Curis

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Curis reports reduced losses, positive clinical data drive growth prospects

Curis demonstrated improved financial performance, strengthened by successful fundraising and promising clinical data, positioning the company for future growth.
While facing challenges in regulatory processes and balancing expenses, Curis remains focused on innovation and market opportunities to drive value creation.
Investors should monitor Curis' upcoming presentations and regulatory developments closely, as positive outcomes could significantly impact the company's trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

29% CR rate observed in R/R AML patients with FLT3 mutation 22% CR/CRh rate observed in R/R AML with spliceosome mutation 45% ORR observed in R/R hrMDS patients with spliceosome mutation Curis to review results during conference call, featuring commentary by Dr. Eric Winer, MD, Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET LEXINGTON, Mass.

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Curis to review results during conference call, featuring commentary  by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m.

Curis to Host Webcast to Discuss Updated Emavusertib Clinical Data in Leukemia

Curis, Inc. (NASDAQ:CRIS ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Craig West – Vice President-Investor Relations and Corporate Communications Jim Dentzer – President and Chief Executive Officer Diantha Duvall – Chief Financial Officer Conference Call Participants Ed White – H.C. Wainwright Soumit Roy – Jones Research Li Watsek – Cantor Fitzgerald Operator Good afternoon, and welcome to Curis' Third Quarter 2022 Business Update Call.

Curis, Inc. (CRIS) Q3 2022 Earnings Call Transcript

Curis (CRIS) delivered earnings and revenue surprises of 17.65% and 6.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q3 Loss, Misses Revenue Estimates

Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022 Curis focuses its resources to drive the development of emavusertib Cash runway extended into 2025 Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Curis Provides Third Quarter 2022 Business Update

LEXINGTON, Mass. , Nov. 7, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2022) being held in Boston, MA and virtually from November 8 th to November 12 th.

Curis Announces Three Presentations at SITC 2022

LEXINGTON, Mass. , Nov. 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the close of U.S. markets.

Curis to Release Third Quarter 2022 Financial Results and Hold Conference Call on November 9, 2022

A look at a couple of drugs in Curis pipeline that could generate some big returns if they are able to gain approval from the FDA. The company should have enough capital to fund operations through 2024.

Curis Is A Speculative Play That Could Produce Solid Returns

Symposium hosted by Guillermo Garcia-Manero, M.D.; Hagop Kantarjian, M.D.

Curis Announces Date for the 1st Symposium on IRAK4 in Cancer

Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle, Ph.D. LEXINGTON, Mass.

Curis Announces Date for the 2nd Annual VISTA Symposium

The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.

Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study

Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass. , Aug. 30, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has notified Curis that it may resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study.

FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study

The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.

Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain

Source: Gorodenkoff / Shutterstock.com Today is a big day for biotech firm Curis (NASDAQ: CRIS ) and CRIS stock. The U.S. Food and Drug Administration (FDA) just completed its review of the company's TakeAim Lymphoma study.

Why Is Curis (CRIS) Stock Up 20% Today?

Curis working with clinical sites to resume enrollment  Preliminary clinical data update expected in 2023 LEXINGTON, Mass. , Aug. 18, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the TakeAim Lymphoma Phase 1/2 study of emavusertib after reviewing the comprehensive data package submitted by Curis.

FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib

Curis, Inc. (NASDAQ:CRIS ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Craig West - VP, IR & Corporate Communications Jim Dentzer - President & CEO Bill Steinkrauss - CFO & Chief Administrative Officer Conference Call Participants Soumit Roy - JonesResearch Li Watsek - Cantor Fitzgerald Bob Martell - Head, Research and Development Operator Good afternoon, everyone, and welcome to Curis' second quarter 2022 earnings conference call. [Operator instructions] At this time, I'd like to turn the conference over to Curis' vice president of investor relations and corporate communications, Craig West.

Curis, Inc. (CRIS) CEO Jim Dentzer on Q2 2022 Results - Earnings Call Transcript

Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential for overcoming ibrutinib resistance at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) Appointed Industry Veteran Diantha Duvall as Chief Financial Officer Strong balance sheet with $107.2 million in cash and investments as of June 30, 2022;  cash runway into 2024 Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.

Curis Reports Second Quarter 2022 Financial Results and Business Update

LEXINGTON, Mass. , July 29, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 22, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of an inducement stock option to purchase a total of 540,000 shares of Curis common stock to a new employee, with a grant date of July 26, 2022, which is the employee's date of hire (the "Inducement Grant").

Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

LEXINGTON, Mass. , July 28, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022, after the close of U.S. markets.

Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022

Applied Genetic Technologies

Alzamend Neuro

Ampio Pharmaceuticals Inc

Bird Rides

DURECT

Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance. The post 6 Penny Stocks With 1,000% Upside Potential appeared first on InvestorPlace.

6 Penny Stocks With 1,000% Upside Potential

Curis share price has had dramatic fall since the FDA announced a hold on their “TakeAim” Leukemia study for Emavusertib on April 4, 2022, following the death of a patient. Recent price action since bottoming has been much more constructive and seems to show accumulation and bullish bets on the name.

Curis: Asymmetric Risk And Reward

Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker IRAK4 along with NF-kB p50/p65 localization to the nucleus is associated with improved response to emavusertib Promising clinical and preclinical analysis showcases the potential of emavusertib in treating pCNSL LEXINGTON, Mass. , June 10, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the presentation of novel findings on biomarker development for IRAK4 inhibitor emavusertib, collaborative work from the University of Florida in primary CNS lymphoma (pCNSL), and clinical data from the TakeAim Leukemia and TakeAim Lymphoma studies at the 2022 European Hematology Association (EHA) Hybrid Congress currently taking place in Vienna, Austria and online until June 12, 2022.

Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress

Curis Inc (NASDAQ: CRIS) presented clinical data from the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology Annual Meeting. The TakeAim Lymphoma Phase 1/2 study is investigating emavusertib as monotherapy and in combination with.

Curis Shares Gain On Encouraging Data Presentation From Blood Cancer Trials At ASCO Meeting

TakeAim Lymphoma data for the combination of emavusertib plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses Potential for overcoming ibrutinib resistance demonstrated with a complete response in a patient who had prior treatment with ibrutinib TakeAim Leukemia data, top-line data previously released in January, highlight emavusertib's single-agent activity in heavily pretreated AML and HR-MDS patients LEXINGTON, Mass. , June 4, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the presentation of encouraging clinical data from both the TakeAim Lymphoma and TakeAim Leukemia studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago and online until June 7, 2022.

Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)

LEXINGTON, Mass. , June 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 11:00 a.m.

News for Curis Stock (CRIS)